Therapeutic immunity by adoptive tumor-primed CD4+ T-cell transfer in combination with in vivo GITR ligation

Molecular Therapy

Volumn 17, Issue 7, 2009, Pages 1274-1281

  Liu, Zuqiang ^a   Tian, Shenghe ^a   Falo Jr , Louis D ^a,b   Sakaguchi, Shimon ^c   You, Zhaoyang ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL TRANSFER; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EX VIVO GENE TRANSFER; FEMALE; HOMEOSTASIS; IN VIVO STUDY; LIGATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PURIFICATION; REGULATORY T LYMPHOCYTE; SPLEEN CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; GLUCOCORTICOID-INDUCED TNFR-RELATED PROTEIN; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES, REGULATORY;

MURINAE; MUS;

EID: 67649875392     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.100     Document Type: Article

References (39)

1. + T lymphocytes: A critical component of antitumor immunity. Cancer Invest 23: 413-419.
2. + T cells in antitumor immune responses. Immunol Rev 222: 129-144.
3. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc Natl Acad Sci USA 96: 8633-8638.
4. + T cells have a major "post-licensing" role in CTL mediated antitumor immunity. J Immunol 165: 6047-6055.
5. + T-cell-dependent tumor eradication in vivo. J Immunol 165: 5495-5501.
6. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174: 2591-2601.
7. Chamoto, K, Wakita, D, Narita, Y, Zhang, Y, Noguchi, D, Ohnishi, H et al. (2006). An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lynph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy. Cancer Res 66: 1809-1817.
8. + TEs provides intratumoral TE proliferation and synergistic antitumor response. Blood 109: 4865-4876.
9. Perez-Diez, A, Joncker, NT, Choi, K, Chan, WFN, Anderson, CC, Lantz, O et al. (2007). CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109: 5346-5354.
10. + T cells. J Immunol 181: 4363-4370.
11. Muranski, P, Boni, A, Antony, PA, Cassard, L, Irvine, KR, Kaiser, A et al. (2008). Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373.
12. + T cells against NY-ESO-1. N Engl J Med 358: 2698-2703.
13. + regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3: 135-142.
14. + immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16: 311-323.
15. Nocentini, G, Ronchetti, S, Cuzzocrea, S and Riccardi, C (2007). GITR/ GITRL: More than an effector T cell co-stimulatory system. Eur J Immunol 37: 1165-1169.
16. + T cells blocks their inhibitory activity: A novel regulatory role for OX40 and its comparison with GITR. Blood 105: 2845-2851.
17. + regulatory T cells. J Exp Med 202: 885-891.
18. Turk, MJ, Guevara-Patino, JA, Rizzuto, GA, Engelhorn, ME, Sakaguchi, S and Houghton, AN (2004). Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200: 771-782.
19. + T-cell responses and tumor immunity. Cancer Res 66: 4904-4912.
20. Ramirez-Montagut, T, Chow, A, Hirschhorn-Cymerman, D, Terwey, TH, Kochman, AA, Lu, S et al. (2006). Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 176: 6434-6442.
21. Ko, HJ, Kim, YJ, Kim, YS, Chang, WS, Ko, SY, Chang, SY et al. (2007). A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 67: 7477-7486.
22. + effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J Immunol 179: 7365-7375.
23. Sharma, S, Dominguez, AL, Manrique, SZ, Cavallo, F, Sakaguchi, S and Lustgarten, J (2008). Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-NeuT tolerant mice. Cancer Res 68: 7530-7540.
24. Calmels, B, Paul, S, Futin, N, Ledoux, C, Stoeckel, F and Acres, B (2005). Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L. Cancer Gene Ther 12: 198-205.
25. Chen, L, Huang, TG, Meseck, M, Mandeli, J, Fallon, J and Woo, SLC (2007). Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol Ther 15: 2194-2202.
26. Hu, P, Arias, RS, Sadun, RE, Nien, YC, Zhang, N, Sabzevari, H et al. (2008). Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer. Clin Cancer Res 14: 579-588.
27. + T cells by bacterial vector. Blood 111: 1404-1412.
28. + T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res 68: 5948-5954.
29. + T cell dependent anti-tumor immunity. Cancer Immunol Immunother (epub ahead of print).
30. Kim, JH, Majumder, N, Lin, H, Chen, J, Falo, LD Jr. and You, Z (2005). Enhanced immunity by NeuEDhsp70 DNA vaccine is needed to combat an aggressive spontaneous metastatic breast cancer. Mol Ther 11 941-949.
31. Lelekakais, M, Moseley, JM, Martin, TJ, Hards, D, Williams, E, Ho, P et al. (1999). A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 17: 163-170.
32. Chaput, N, Darrasse-Jeze, G, Bergot, AS, Cordier, C, Ngo-Abdalla, S, Klatzmann, D et al. (2007). Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J Immunol 179: 4969-4978.
33. Bunt, SK, Yang, L, Sinha, P, Clements, VK, Leips, J and Ostrand-Rosenberg, S (2007). Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67: 10019-10026.
34. Liu, Z, Kim, JH, Falo, LD Jr. and You, Z. Tumor Treg potently abrogate antitumor immunity. J Immunol (epub ahead of print).
35. Reilly, RT, Gottlieb, MBC, Ercolini, AM, Machiels, JPH, Kane, CE, Okoye, FI et al. (2000). Her-2/neu is a tumor rejection target in tolerized Her-2/neu transgenic mice. Cancer Res 60: 3569-3576.
36. - lymphocytes is thymus and proliferation independent. Cancer Res 66: 4488-4495.
37. Uno, T, Takeda, K, Kojima, Y, Yoshizawa, H, Akiba, H, Mittler, RS et al. (2006). Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 12: 693-698.
38. Luznik, L, Slansky, JE, Jalla, S, Borrello, I, Levitsky, HI, Pardoll, DM et al. (2003). Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood 101 1645-1652.
39. Siegmund, K, Feuerer, M, Siewert, C, Ghani, S, Haubold, U, Dankof, A et al. (2005). Migration matters: Regulatory T-cell compartmentalization determines suppressive activity in vivo. Blood 106: 3097-3104.